Liu Haibei, Luo Rong, Qian Liu, Zhang Yujun, Zhang Wensheng, Tan Juan, Ye Ling
Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China.
Laboratory of Anesthesia and Critical Care Medicine, National-Local Joint Engineering Research Center of Translational Medicine of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China.
BMC Anesthesiol. 2024 Dec 19;24(1):456. doi: 10.1186/s12871-024-02845-7.
Major abdominal surgery is a kind of high-risk surgery type for postoperative acute kidney injury (AKI) among non-cardiac surgeries. Despite dexmedetomidine exerts significant renal protective effects in cardiac surgeries and animal studies, whether it is associated with a lower incidence of AKI in major abdominal surgeries remains unclear.
From January 2019 to July 2021, patients undergoing elective major abdominal surgery in West China Hospital were enrolled. Participants were divided into two groups based on exposure to continuous intravenous dexmedetomidine: the Dex group (exposed) and the Control group (not exposed). The primary outcome was the incidence of AKI in the postoperative 7 days. Secondary outcomes included intraopertive average urine output, renal function on the first day after surgery, incidence of postoperative dialysis, postoperative intensive care unit (ICU) admission, in-hospital mortality, length of hospital stay, incidence of intraoperative hypotension and bradycardia, and intraoperative use of inotropes and vasopressors. Propensity score matching (PSM), based on participants' baseline and intraoperative characteristics, was performed to minimize potential bias. Furthermore, a subgroup analysis was conducted based on the infusion rate and the use of a loading dose to explore the effects of different methods of dexmedetomidine administration on AKI. The subgroups included: loading dose, non-loading dose, low-infusion rate (infusion rate ≤ 0.4 µg/kg/h), and high-infusion rate (infusion rate > 0.4 µg/kg/h).
After PSM with a ratio of 1:1, a total of 8836 patients were successfully matched. Dexmedetomidine administration had no association with the incidence of postoperative AKI, serum creatinine (Scr) level on the first postoperative day, incidence of postoperative dialysis, postoperative ICU admission, in-hospital mortality, length of hospital stay, intraoperative hypotension, or the use of inotropes and vasopressors, but had association with increased intraoperative average urine output (122.95 (76.80, 189.27) vs. 104.65 (67.04, 161.07) ml/h, P < 0.001), higher value of estimated glomerular filtration rate (eGFR) (97.33 ± 15.95 vs. 96.13 ± 16.35 ml/min/1.73m, P < 0.001) on the first day after surgery and a higher incidence of intraoperative bradycardia (37.0% vs. 30.6%; P < 0.001). In the loading dose subgroup, dexmedetomidine use was significantly associated with a reduced incidence of postoperative AKI (odds ratio (OR): 0.44, 95% confidence interval (CI): 0.23-0.76, P = 0.006).The association between dexmedetomidine and postoperative AKI was absent in subgroups of high or low infusion rate and no loading dose use.
In this single-center retrospective propensity-matched study, we did not detect a significant overall difference in post-operative AKI rates between patients treated with or without dexmedetomidine during major abdominal surgery. However, though additional prospective data are needed, our study found that administering dexmedetomidine with a loading dose may be associated with lower rates of AKI, potentially indicating a renoprotective effect of loading-dose dexmedetomidine in this setting.
在非心脏手术中,腹部大手术是术后发生急性肾损伤(AKI)的一种高风险手术类型。尽管右美托咪定在心脏手术和动物研究中具有显著的肾脏保护作用,但在腹部大手术中其是否与较低的AKI发生率相关仍不清楚。
纳入2019年1月至2021年7月在华西医院接受择期腹部大手术的患者。根据是否持续静脉输注右美托咪定将参与者分为两组:右美托咪定组(暴露组)和对照组(未暴露组)。主要结局是术后7天内AKI的发生率。次要结局包括术中平均尿量、术后第一天的肾功能、术后透析发生率、术后入住重症监护病房(ICU)、院内死亡率、住院时间、术中低血压和心动过缓的发生率以及术中使用血管活性药物的情况。基于参与者的基线和术中特征进行倾向评分匹配(PSM),以尽量减少潜在偏倚。此外,根据输注速率和负荷剂量的使用情况进行亚组分析,以探讨右美托咪定不同给药方法对AKI的影响。亚组包括:负荷剂量组、非负荷剂量组、低输注速率组(输注速率≤0.4μg/kg/h)和高输注速率组(输注速率>0.4μg/kg/h)。
经过1:1比例的PSM后,共成功匹配8836例患者。使用右美托咪定与术后AKI的发生率、术后第一天的血清肌酐(Scr)水平、术后透析发生率、术后入住ICU、院内死亡率、住院时间、术中低血压或血管活性药物的使用均无关,但与术中平均尿量增加有关(122.95(76.80,189.27) vs. 104.65(67.04,161.07)ml/h,P<0.001),术后第一天估算肾小球滤过率(eGFR)值更高(97.33±15.95 vs. 96.13±16.35 ml/min/1.73m,P<0.001),且术中心动过缓的发生率更高(37.0% vs. 30.6%;P<0.001)。在负荷剂量亚组中,使用右美托咪定与术后AKI发生率降低显著相关(比值比(OR):0.44,95%置信区间(CI):0.23 - 0.76,P = 0.006)。在高或低输注速率且未使用负荷剂量的亚组中,右美托咪定与术后AKI之间无关联。
在这项单中心回顾性倾向匹配研究中,我们未发现腹部大手术期间使用或未使用右美托咪定的患者术后AKI发生率存在显著总体差异。然而,尽管需要更多前瞻性数据,但我们的研究发现,使用负荷剂量的右美托咪定可能与较低的AKI发生率相关,这可能表明在此情况下负荷剂量右美托咪定具有肾脏保护作用。